Previous 10 |
home / stock / trgnf / trgnf news
Transgene S.A. ( OTCPK:TRGNF ): 1H GAAP EPS of -€0.24. More news on: TRANSGENE S.A., Earnings news and commentary, Tech stocks news, , Read more ...
Deals and Financings Tasly Biopharma (SHA:600535) of Shanghai raised $84.5 million in new capital from a group of investors that included Ally Bridge. The funding is a pre-IPO round as Tasly is planning to list on the Hong Kong Exchange. The investors received a 4.5% stake in Tasly Biopharma...
Transgene S.A. ( OTCPK:TRGNF ): Q1 Revenue of €1.8M (-5.3% Y/Y) Cash and Cash equivalents of €35.6M. Press Release More news on: TRANSGENE S.A., Earnings news and commentary, Tech stocks news, ,
In an update to investors, French biotech Transgene ( OTCPK:TRGNF ) lists key expected events for 2018: More news on: TRANSGENE S.A., Bristol-Myers Squibb Company, Pfizer Inc., Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Transgene S.A. Company Name:
TRGNF Stock Symbol:
OTCMKTS Market:
Strasbourg, France, and Lund, Sweden, July 22, 2024, 8:00 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and BioInvent International AB (“BioInvent”) (Nasdaq Stock...
Patient screening and enrollment initiated for the Phase II part of the international randomized Phase I/II trial with an overall sample size of approximately 80 patients. Last patient enrollment for Phase II part expected in Q4 2025. Strasbourg, France, June 3, 2024, 7:30 a....
TG4050: Exciting Phase I data presented at AACR 2024 demonstrating first signs of clinical benefit in adjuvant setting for head and neck cancer Phase II part of randomized trial to start in coming weeks New clinical data expected on TG4001, TG6050 and BT-001 in H2 2024 Financial vis...